Global Cervical Cancer Diagnostics & Therapeutics Market Analysis, Growth, Trends & Forecasts 2018-2023, With an Expected CAGR of 6.3% - ResearchAndMarkets.com
Aug. 03, 2018
DUBLIN--(BUSINESS WIRE)--Aug 3, 2018--The "Global Cervical Cancer Diagnostics and Therapeutics Market - Segmented by Diagnostic Test, By Therapeutics, End Users - Growth, Trends and Forecasts (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global cervical cancer diagnostics and therapeutics market is expected to register a CAGR of 6.3% during the forecast period, 2018 to 2023.
The United States assists with coverage and reimbursement on Pap test screening. Federal law has been passed by the Affordable Care Act (ACA) to mandate the coverage of cervical cancer screening tests. It is also supported by self-insured plans. Medicaid, the most popular government insurance program covers screening for cervical cancers. Medicare, another widely used insurance covers Pap test, pelvic exam, and a clinical breast exam for cervical cancer screening every two years for Medicare beneficiaries.
In middle-income and low-income developing countries, the existing programs are failing to create major impact. This failure is mostly attributed to the lack of or in many cases the absence of a healthcare system that is capable of providing the diagnostic and treatment services inseparable from screening. Many countries of Asia-Pacific and Africa lack a proper healthcare infrastructure to provide the basic medical amenities to people living in rural, and underdeveloped areas.
Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of cervical cancer. The high prevalence rate of cervical cancer among the population has attributed to factors, such as less awareness regarding sexual hygiene and precaution.
Companies MentionedAbbott. Advaxis Inc. Becton Dickinson And Company Bristol-Meyrs Squibb Company F. Hoffmann-La Roche Ltd. Glaxosmithkline Plc Qiagen N.V Merck & Co. Inc. Pfizer Inc. Quest Diagnostics Inc.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/qsl6v7/global_cervical?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180803005342/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/03/2018 10:36 AM/DISC: 08/03/2018 10:36 AM